Loading
Oncorine is Shanghai Sunway Biotech's oncolytic adenovirus, approved in China in 2005 for nasopharyngeal carcinoma with chemotherapy, the first oncolytic virus approved anywhere in the world.
H101 (Oncorine) is an E1B-55K-deleted adenovirus derived from the same design as ONYX-015, developed by Shanghai Sunway Biotech. The NMPA (then the SFDA) approved it in November 2005 for late-stage nasopharyngeal carcinoma in combination with chemotherapy, ten years before talimogene laherparepvec became the first oncolytic virus approved in the United States. It is injected into the tumour.
An adenovirus lacking the E1B-55K gene replicates only in cells with a broken p53 pathway, bursting tumour cells and alerting the immune system.
1.H101 oncolytic adenovirus slips into a pocket on its target.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| CN | 2005 | Late-stage nasopharyngeal carcinoma, with chemotherapy |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"H101 oncolytic adenovirus" OR ABSTRACT:"H101 oncolytic adenovirus" OR TITLE:"H101" OR ABSTRACT:"H101" OR TITLE:"Oncorine" OR ABSTRACT:"Oncorine") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about H101 oncolytic adenovirus, not a curated reading list.
Shares Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients and the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.